All In Biotech

Drug Trial Radar · NCT05058391

A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

A Prospective, Multicenter, Single-arm, Open-label, Interventional Phase IV Study to Evaluate the Safety and Efficacy of Idursulfase (r-DNA Origin) (Elaprase™) in Indian Pediatric and Adult Population With Hunter Syndrome (Mucopolysaccharidosis II)

Last checked: Nov 20, 2026Latest source record: Jan 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

5

Actual

Start

Apr 21, 2022

Primary completion

Apr 6, 2024

Study completion Apr 18, 2024

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to learn more about the safety profile of Elaprase in Indian children and adults with hunter syndrome. Participants will receive Elaprase once per week over a 3-hour period which can be reduced to 1 hour as determined by the study doctor. Participants will need to visit the clinic weekly during the duration of the study.

Conditions

  • Hunter Syndrome

Interventions

  • ElapraseBiological

    Elaprase IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Discontinuation Due to TEAEs and DeathTime frame: From start of the study drug administration up to Week 53
  2. Number of Participants With Adverse Drug Reactions (ADRs)Time frame: From start of the study drug administration up to Week 53
  3. Number of Participants With Infusion-related Reactions (IRRs)Time frame: From start of the study drug administration up to Week 53

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Institute of Child Health

    Kolkata, India

  • All India Institute of Medical Sciences (AIIMS)

    New Delhi, India

  • Sir Gangaram Hospital

    New Delhi, India

  • SAT Hospital - Govt Medical College

    Thiruvananthapuram, Kerala, India

  • JK Lone Hospital

    Jaipur, Rajasthan, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.